Cultivating New Frontiers
of Science
Across its two-decade history, TCG has funded key advancements within biotechnology, nurturing science into successful ventures and therapeutic breakthroughs.
Fueling Life Sciences
Innovation Across the Life
Cycle of Opportunity
TCG deploys an edge-to-edge investment model, harnessing an ecosystem of funds that propel early technology platforms, single assets and later-stage programs forward from inception through exit.
Returns
$ Billion
TCG has generated $4.0 billion in returns for its partners and portfolio.
Innovation
Companies
Across its two-decade history, TCG has nurtured science into successful biotech ventures, having started and invested in 55 companies.
Impact
Exits
TCG has funded key advancements within biology, chemistry and technology, leading to 18 company exits.
The TCG Ecosystem
Pursuing the Unprecedented
TCG takes a novel approach to venture capital funding with an edge-to-edge investment model primarily focused on company formation but with the financial wherewithal for long-term private and public capital support. This model exists within an ecosystem of funds, each with a clear strategy and focus, and all with a mandate of maximizing success through collaborative action. TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil and TCG Crossover (TCGX) wield complementary approaches for deploying capital and work together to propel technology platforms, single assets and later-stage programs forward from inception through exit.
Portfolio
"At TCG, we are committed to supporting our portfolio from inception to exit. This includes identifying key leadership early on and taking a hands-on approach to guide companies through critical growth phases. We collaborate with our portfolio to recruit top talent at every level, ensuring they have the expertise to thrive."
"The TCG team is all about the science. They are pioneers – visionaries who believe in achieving unprecedented progress, while always being anchored in exemplary science."
"TCG is really unique. They are deeply committed and have taught me how to build a company the right way. Members of their leadership team would come to our office weekly, and we talked every day. As a newly formed company, you really want an investor like that – it is exactly what we needed."
"TCG is differentiated as a firm with deep fundamental scientific principles. They support strong scientifically-driven teams taking big innovative leaps towards changes for patients."
"There are a lot of medicines that never would have moved forward, that never would have made it to the clinic – or to a patient – if not for TCG. They have the expertise to know when to lean in, investing in smart people and creative science, and it has paid off."
"TCG is a sophisticated biotech investor. They understand that scientific breakthroughs take time and resilience, and they have always been there for us even during tough times. They are visionary and have the courage to invest in transformative science that may take years to execute."
"The TCG team is highly committed to company formation and great science, but more importantly, they are dedicated to mentoring CEOs. As a first-time CEO, TCG promised to stand by me, the company and the science, and to help get it funded. They did just that and then some."
"The Swanson Fellowship is a launchpad for anyone seeking to establish themselves as a lifelong leader in biotech. TCG empowers early-career individuals with unparalleled resources, mentorship, and access to the academic and industry networks required to build transformative drug development enterprises."
In The News
Featured news from our team and portfolio
Portfolio News